Supplementary Table 2. Patient baseline characteristics of naïve patients

	MET (n=27)	Sorafenib (n=16)	*P*-value
Mean age±SD (yrs)	53.8±11.8	59.1±8.0	0.116
Gender			0.043
Male	25 (92.6)	11 (68.8)	
Female	2 (7.4)	5 (31.2)	
Etiology			0.513
HBV	22 (81.5)	12 (75.0)	
HCV	3 (11.1)	1 (6.2)	
Alcohol	2 (7.4)	2 (12.5)	
Others	0 (0.0)	1 (6.2)	
Child-Pugh class			0.410
A	10 (37.0)	8 (50.0)	
B	17 (63.0)	8 (50.0)	
Child-Pugh score			0.718
5	3 (11.1)	2 (12.5)	
6	7 (25.9)	6 (37.5)	
7	8 (29.6)	2 (12.5)	
8	5 (18.5)	4 (25.0)	
9	4 (14.8)	2 (12.5)	
Tumor maximal diameter	14.0±4.2	12.1±5.4	0.205
Tumor number			0.412
Solitary	4 (14.8)	4 (25.0)	
Multiple	23 (85.2)	12 (75.0)	
PVTT			1.000
Vp2	3 (11.1)	4 (25.0)	
Vp3	13 (48.1)	4 (25.0)	
Vp4	11 (40.7)	8 (50.0)	
Extrahepatic metastasis	15 (55.6)	13 (81.2)	0.091
mUICC			0.115
III	2 (7.4)	1 (6.2)	
IVA	10 (37.0)	2 (12.5)	
IVB	15 (55.6)	13 (81.2)	
Serum AFP level (ng/dL)			0.539
<400	11 (40.7)	5 (31.2)	
≥400	16 (59.3)	11 (68.8)	

Values are presented as mean±SD or n (%).
MET, metronomic chemotherapy; HBV, hepatitis B virus; HCV, hepatitis C virus; PVTT, portal vein tumor thrombosis; mUICC, modified UICC staging; AFP, alpha-fetoprotein.

https://doi.org/10.3350/cmh.2016.0071